The RNA editing therapies market is witnessing rapid growth as researchers develop precise RNA-based treatments for rare and genetic disorders. These therapies offer reversible, targeted interventions without permanent DNA changes. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. RNA Editing Therapies Market Revenue and Volume, by Editing Modality / Mechanism
7.1.1. ADAR-recruiting RNA base editing (A→I/G)
7.1.1.1. Market Revenue and Volume Forecast
7.1.2. RNA exon editing / RNA trans-splicing (multi-kilobase exon replacement)
7.1.2.1. Market Revenue and Volume Forecast
7.1.3. Programmable oligonucleotide editors (guide oligos that recruit endogenous editors)
7.1.3.1. Market Revenue and Volume Forecast
7.1.4. RNA-guided deaminases / engineered RNA editors (protein-RNA editor fusions)
7.1.4.1. Market Revenue and Volume Forecast
7.1.5. Transient RNA knockdown + re-write hybrid approaches
7.1.5.1. Market Revenue and Volume Forecast
7.1.6. ADAR-recruiting AI-based editing
7.1.6.1. Market Revenue and Volume Forecast
7.1.7. RNA exon editing (kilobase-scale replacement)
7.1.7.1. Market Revenue and Volume Forecast
8.1. RNA Editing Therapies Market Revenue and Volume, by Therapeutic Intent
8.1.1. One-time durable/edit-permanent-feeling RNA interventions (long-lasting exon edits)
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Repeat-dosed corrective editing (ASO-like dosing to sustain edits)
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Symptom-modifying RNA edits (modulate expression or splicing)
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Combination regimens (RNA edit + supportive biologic)
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Repeat-dosed corrective editing
8.1.5.1. Market Revenue and Volume Forecast
8.1.6. One-time durable RNA exon editors
8.1.6.1. Market Revenue and Volume Forecast
9.1. RNA Editing Therapies Market Revenue and Volume, by Delivery Platform
9.1.1. AAV-mediated delivery (viral vectors for in vivo CNS / ocular / systemic)
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Lipid nanoparticle (LNP) delivery (systemic, liver-focused)
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Conjugated oligo delivery (GalNAc, peptide conjugates for tissue targeting)
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Localized/intrathecal delivery (CNS-targeted administration)
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Non-viral nanoparticle / novel carriers
9.1.5.1. Market Revenue and Volume Forecast
10.1. RNA Editing Therapies Market Revenue and Volume, by Indication / Disease Area
10.1.1. Rare genetic liver diseases (e.g., AATD)
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Rare retinal & ocular genetic diseases
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Neurological rare diseases (SMA subtypes, ataxias)
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Metabolic & systemic genetic disorders
10.1.4.1. Market Revenue and Volume Forecast
10.1.5. Common chronic diseases
10.1.5.1. Market Revenue and Volume Forecast
11.1. RNA Editing Therapies Market Revenue and Volume, by Product Type
11.1.1. Single-molecule RNA editors (synthetic oligos recruiting endogenous enzymes)
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Vector-encoded RNA editor constructs (AAV/LV delivered editor expression)
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Combination drug-device (editor + intrathecal delivery implant)
11.1.3.1. Market Revenue and Volume Forecast
11.1.4. Platform-licensed programs (partnered IP)
11.1.4.1. Market Revenue and Volume Forecast
12.1. RNA Editing Therapies Market Revenue and Volume, by Mode of Administration
12.1.1. Intravenous systemic dosing
12.1.1.1. Market Revenue and Volume Forecast
12.1.2. Subcutaneous/conjugated subcutaneous dosing
12.1.2.1. Market Revenue and Volume Forecast
12.1.3. Intrathecal/intraventricular injection for CNS
12.1.3.1. Market Revenue and Volume Forecast
12.1.4. Intravitreal ocular injection
12.1.4.1. Market Revenue and Volume Forecast
12.1.5. Localized tissue injection / catheter-based delivery
12.1.5.1. Market Revenue and Volume Forecast
13.1. RNA Editing Therapies Market Revenue and Volume, by Distribution & Commercial Channel
13.1.1. Hospital & specialist clinic administration (infusion/injection sites)
13.1.1.1. Market Revenue and Volume Forecast
13.1.2. Specialty pharmacy + manufacturer hub logistics
13.1.2.1. Market Revenue and Volume Forecast
13.1.3. Direct-to-clinic manufacturer logistics for complex vector deliveries
13.1.3.1. Market Revenue and Volume Forecast
14.1. North America
14.1.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.1.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.1.3. Market Revenue and Volume Forecast, by Delivery Platform
14.1.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.1.5. Market Revenue and Volume Forecast, by Product Type
14.1.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.1.7. Market Revenue and Volume Forecast, by Mode of Administration
14.1.8. U.S.
14.1.8.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.1.8.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.1.8.3. Market Revenue and Volume Forecast, by Delivery Platform
14.1.8.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.1.8.5. Market Revenue and Volume Forecast, by Product Type
14.1.8.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.1.8.7. Market Revenue and Volume Forecast, by Mode of Administration
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.1.9.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.1.9.3. Market Revenue and Volume Forecast, by Delivery Platform
14.1.9.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.1.9.5. Market Revenue and Volume Forecast, by Product Type
14.1.9.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.1.9.7. Market Revenue and Volume Forecast, by Mode of Administration
14.2. Europe
14.2.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.2.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.2.3. Market Revenue and Volume Forecast, by Delivery Platform
14.2.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.2.5. Market Revenue and Volume Forecast, by Product Type
14.2.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.2.7. Market Revenue and Volume Forecast, by Mode of Administration
14.2.8. UK
14.2.8.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.2.8.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.2.8.3. Market Revenue and Volume Forecast, by Delivery Platform
14.2.8.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.2.8.5. Market Revenue and Volume Forecast, by Product Type
14.2.8.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.2.8.7. Market Revenue and Volume Forecast, by Mode of Administration
14.2.9. Germany
14.2.9.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.2.9.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.2.9.3. Market Revenue and Volume Forecast, by Delivery Platform
14.2.9.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.2.9.5. Market Revenue and Volume Forecast, by Product Type
14.2.9.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.2.9.7. Market Revenue and Volume Forecast, by Mode of Administration
14.2.10. France
14.2.10.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.2.10.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.2.10.3. Market Revenue and Volume Forecast, by Delivery Platform
14.2.10.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.2.10.5. Market Revenue and Volume Forecast, by Product Type
14.2.10.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.2.10.7. Market Revenue and Volume Forecast, by Mode of Administration
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.2.11.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.2.11.3. Market Revenue and Volume Forecast, by Delivery Platform
14.2.11.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.2.11.5. Market Revenue and Volume Forecast, by Product Type
14.2.11.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.2.11.7. Market Revenue and Volume Forecast, by Mode of Administration
14.3. APAC
14.3.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.3.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.3.3. Market Revenue and Volume Forecast, by Delivery Platform
14.3.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.3.5. Market Revenue and Volume Forecast, by Product Type
14.3.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.3.7. Market Revenue and Volume Forecast, by Mode of Administration
14.3.8. India
14.3.8.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.3.8.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.3.8.3. Market Revenue and Volume Forecast, by Delivery Platform
14.3.8.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.3.8.5. Market Revenue and Volume Forecast, by Product Type
14.3.8.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.3.8.7. Market Revenue and Volume Forecast, by Mode of Administration
14.3.9. China
14.3.9.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.3.9.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.3.9.3. Market Revenue and Volume Forecast, by Delivery Platform
14.3.9.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.3.9.5. Market Revenue and Volume Forecast, by Product Type
14.3.9.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.3.9.7. Market Revenue and Volume Forecast, by Mode of Administration
14.3.10. Japan
14.3.10.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.3.10.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.3.10.3. Market Revenue and Volume Forecast, by Delivery Platform
14.3.10.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.3.10.5. Market Revenue and Volume Forecast, by Product Type
14.3.10.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.3.10.7. Market Revenue and Volume Forecast, by Mode of Administration
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.3.11.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.3.11.3. Market Revenue and Volume Forecast, by Delivery Platform
14.3.11.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.3.11.5. Market Revenue and Volume Forecast, by Product Type
14.3.11.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.3.11.7. Market Revenue and Volume Forecast, by Mode of Administration
14.4. MEA
14.4.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.4.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.4.3. Market Revenue and Volume Forecast, by Delivery Platform
14.4.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.4.5. Market Revenue and Volume Forecast, by Product Type
14.4.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.4.7. Market Revenue and Volume Forecast, by Mode of Administration
14.4.8. GCC
14.4.8.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.4.8.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.4.8.3. Market Revenue and Volume Forecast, by Delivery Platform
14.4.8.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.4.8.5. Market Revenue and Volume Forecast, by Product Type
14.4.8.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.4.8.7. Market Revenue and Volume Forecast, by Mode of Administration
14.4.9. North Africa
14.4.9.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.4.9.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.4.9.3. Market Revenue and Volume Forecast, by Delivery Platform
14.4.9.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.4.9.5. Market Revenue and Volume Forecast, by Product Type
14.4.9.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.4.9.7. Market Revenue and Volume Forecast, by Mode of Administration
14.4.10. South Africa
14.4.10.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.4.10.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.4.10.3. Market Revenue and Volume Forecast, by Delivery Platform
14.4.10.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.4.10.5. Market Revenue and Volume Forecast, by Product Type
14.4.10.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.4.10.7. Market Revenue and Volume Forecast, by Mode of Administration
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.4.11.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.4.11.3. Market Revenue and Volume Forecast, by Delivery Platform
14.4.11.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.4.11.5. Market Revenue and Volume Forecast, by Product Type
14.4.11.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.4.11.7. Market Revenue and Volume Forecast, by Mode of Administration
14.5. Latin America
14.5.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.5.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.5.3. Market Revenue and Volume Forecast, by Delivery Platform
14.5.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.5.5. Market Revenue and Volume Forecast, by Product Type
14.5.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.5.7. Market Revenue and Volume Forecast, by Mode of Administration
14.5.8. Brazil
14.5.8.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.5.8.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.5.8.3. Market Revenue and Volume Forecast, by Delivery Platform
14.5.8.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.5.8.5. Market Revenue and Volume Forecast, by Product Type
14.5.8.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.5.8.7. Market Revenue and Volume Forecast, by Mode of Administration
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Volume Forecast, by Editing Modality / Mechanism
14.5.9.2. Market Revenue and Volume Forecast, by Therapeutic Intent
14.5.9.3. Market Revenue and Volume Forecast, by Delivery Platform
14.5.9.4. Market Revenue and Volume Forecast, by Indication / Disease Area
14.5.9.5. Market Revenue and Volume Forecast, by Product Type
14.5.9.6. Market Revenue and Volume Forecast, by Distribution & Commercial Channel
14.5.9.7. Market Revenue and Volume Forecast, by Mode of Administration
15.1. ADARx Pharmaceuticals
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Amber Bio
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Ascidian Therapeutics
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Beam Therapeutics (adjacent base/editing capabilities)
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Catalent (CDMO / delivery & manufacturing partner)
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. GSK (strategic partner/investor in RNA editing programs)
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Korro Bio
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Moderna (delivery & RNA platform capabilities)
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. ProQR Therapeutics (Axiomer ADAR-recruiting tech)
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Regenxbio
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description